Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5481469 | 1.00 | MEN1 (0.63) | MEN1KMT2AKDM4EPOLBRAB9A | |
| SCHEMBL5472420 | 0.93 | SMN1; SMN2 (0.64) | MEN1KMT2AKDM4EPOLBRAB9A | |
| SCHEMBL5472424 | 0.93 | SMN1; SMN2 (0.64) | MEN1KMT2AKDM4EPOLBRAB9A | |
| SCHEMBL5243826 | 0.82 | MEN1 (0.72) | MEN1KMT2AKDM4EPOLBRAB9A | |
| SCHEMBL5282637 | 0.82 | MEN1 (0.72) | MEN1KMT2AKDM4EPOLBRAB9A | |
| SCHEMBL5475817 | 0.82 | MAPT (0.76) | MEN1KMT2AKDM4EPOLBALDH1A1 | |
| SCHEMBL5475819 | 0.82 | MAPT (0.76) | MEN1KMT2AKDM4EPOLBALDH1A1 | |
| SCHEMBL5244127 | 0.82 | MEN1 (0.72) | MEN1KMT2AKDM4EPOLBRAB9A | |
| SCHEMBL5244399 | 0.77 | EPHX2 (0.77) | MEN1KMT2AKDM4EPOLBRAB9A | |
| SCHEMBL5242567 | 0.77 | EPHX2 (0.77) | MEN1KMT2AKDM4EPOLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070112000-A1 | Chemical compounds | ASTRAZENECA R&D ALDERLEY (GB) | 2007-05-17 | — | — | US | claimed |
| EP-1684757-A1 | SUBSTITUTED PIPERIDINES FOR THE TREATMENT OF METABOLIC SYNDROME | AstraZeneca AB (SE) | 2006-08-02 | — | — | EP | claimed |
| WO-2005046685-A1 | SUBSTITUTED PIPERIDINES FOR THE TREATMENT OF METABOLIC SYNDROME | ASTRAZENECA AB (SE) | 2005-05-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112000-A1 | Chemical compounds | HSD11B1, CYP11B1, HSD11B2 | MEN1 1206/4885KMT2A 2279/4885KDM4E 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.